Welcome to our dedicated page for Uniqure SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
uniQure N.V. filings document regulatory, financial, governance, and capital-structure disclosures for a Nasdaq-listed gene therapy company incorporated in the Netherlands. Form 8-K reports cover operating results, corporate updates, Regulation FD disclosures, and clinical or regulatory communications involving programs such as AMT-130 for Huntington’s disease.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also includes formal disclosure categories for material agreements, financing arrangements, risk-related updates, and capital-structure matters connected to uniQure’s development-stage gene therapy portfolio.
uniQure N.V. filed an Amendment No. 4 to a Schedule 13G/A reporting shared beneficial ownership of 2,586,356 Ordinary Shares. The filing states this represents 4.1% of the class based on 62,529,408 Shares outstanding as of February 26, 2026. The reporting persons are RTW Investments, LP and Roderick Wong, M.D., reporting shared voting and dispositive power over the same 2,586,356 shares. The statement notes the RTW Funds have the right to receive dividends or proceeds from these Shares.
uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an exercise-and-sell transaction in Ordinary Shares. On May 8, 2026, he sold a total of 45,000 Ordinary Shares in open-market transactions at weighted-average prices around $25.00–$25.29, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 26, 2025.
On the same date, he exercised 25,000 stock options with a $5.59 exercise price, receiving an equal number of Ordinary Shares. After these transactions, he directly held 169,669 Ordinary Shares and 60,500 stock options expiring on March 1, 2034, indicating he retains a substantial equity stake.
State Street Corporation reports shared beneficial ownership of 2,260,512 shares of Uniqure N.V. common stock, representing 3.6% of the class as reported on 03/31/2026. The filing lists shared voting power of 2,230,049 and identifies affiliated investment adviser entities.
The filing is a Schedule 13G disclosure showing passive/beneficial ownership by institutional holders and names SSGA Funds Management, State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company and State Street Global Advisors, Ltd. as related entities.
Uniqure N.V. submitted a Form 144 notice reporting proposed sales of Ordinary Shares to be effected through Citigroup Global Markets, Inc. on 05/08/2026. The filing lists 45,000 (figure present) and details 20,000 vested shares and 25,000 shares from option exercises.
FMR LLC filed an amendment to Schedule 13G reporting beneficial ownership of 1,743,807.87 shares of UNIQURE N.V. common stock, representing 2.8% of the class. The filing lists sole dispositive power for 1,743,807.87 shares and sole voting power of 1,741,237 shares. The cover names Abigail P. Johnson in connection with FMR LLC and references an exhibit for a 13d-1(k)(1) agreement.
uniQure N.V. reported first quarter 2026 results showing a net loss of $53.5 million, or $0.85 per share, compared with a $43.6 million loss a year earlier. Revenue rose to $3.6 million from $1.6 million, mainly from higher license revenue.
The company ended March 31, 2026 with $586.6 million in cash, cash equivalents and current investment securities and expects this to fund operations into the second half of 2029. Research and development expenses fell to $29.2 million, while selling, general and administrative expenses increased to $20.1 million, reflecting hiring for AMT-130 commercial planning.
uniQure highlighted pipeline progress, including ongoing FDA interactions for AMT-130 in Huntington’s disease with a Type B meeting planned in the second quarter of 2026 and a targeted UK marketing authorization application submission in the third quarter of 2026. Additional 2026 updates are expected from AMT-260 in mesial temporal lobe epilepsy, AMT-191 in Fabry disease and AMT-162 in SOD1 ALS.
Aberdeen Group plc and abrdn Inc. report beneficial ownership of 5,306,386 ordinary shares of uniQure N.V., representing 8.49% of the class. The filing states shared voting and dispositive power for 5,306,386 shares. The disclosure is submitted by a parent and intermediate holding structure and signed by a Major Shareholding Reporting Analyst on 03/31/2026.
uniQure N.V. announced a successful pre-submission meeting with the UK Medicines and Healthcare products Regulatory Agency for AMT-130, its investigational gene therapy for Huntington’s disease. The company plans to submit a UK Marketing Authorization Application in the third quarter of 2026.
The planned submission will be based on three-year data from ongoing U.S. and European Phase I/II trials, where high-dose AMT-130 showed a statistically significant 75% slowing of disease progression on a composite Huntington’s scale versus a matched external control (p=.003) and was generally well-tolerated with a manageable safety profile.
uniQure has also been granted a Type B meeting with the U.S. Food and Drug Administration in the second quarter of 2026 to discuss a potential Phase III trial design and the statistical analysis plan for a four-year data readout expected in the third quarter of 2026, while pursuing additional ex-US regulatory pathways.